Sunrun Inc vs Summit Therapeutics Inc — how do they compare? Sunrun Inc trades at $9.8 (market cap $2.42B), while Summit Therapeutics Inc trades at $15.26 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 5× Sunrun Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| RUN | SMMT | |
|---|---|---|
Market Cap | $2.42B | $12.06B |
Sector | Technology | Health |
52-Week High | $21.41 | $26.98 |
52-Week Low | $9.38 | $12.55 |
Enterprise Value | $16.93B | $11.39B |
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $9.79, down 0.81% amid bearish technical signals despite strong earnings beats. The company shows solid profitability with 11.59% net margin and attractive valuation metrics including P/E of 6.82 and P/B of 0.69. Recent Q2 2026 results beat expectations with $0.42 EPS versus $0.23 estimate, though shares declined on reduced full-year guidance and Goldman Sachs price target cut from $18 to $15.
While fundamentals remain strong with growing storage adoption and positive cash generation, near-term headwinds include guidance reductions and solar sector volatility. Analyst consensus remains bullish with $14.38 price target representing 47% upside potential, but investors face execution risks amid the company's shift toward direct sales and competitive market pressures.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Trailing returns across standard periods
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →